company background image
RPRX

Royalty Pharma NasdaqGS:RPRX Stock Report

Last Price

US$26.61

Market Cap

US$16.0b

7D

-4.9%

1Y

-33.3%

Updated

25 Sep, 2023

Data

Company Financials +

RPRX Stock Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.

RPRX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health3/6
Dividends1/6

Royalty Pharma plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Royalty Pharma
Historical stock prices
Current Share PriceUS$26.61
52 Week HighUS$44.47
52 Week LowUS$25.92
Beta0.40
1 Month Change-11.92%
3 Month Change-10.82%
1 Year Change-33.27%
3 Year Change-35.43%
5 Year Changen/a
Change since IPO-40.20%

Recent News & Updates

Recent updates

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Royalty Pharma declares $0.19 dividend

Jul 15

Royalty Pharma: Unique Diversification, Bear Market Performer

May 26

The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Apr 25
The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma Offers A Unique Long-Term Investment Opportunity

Mar 01

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19

Jan 25
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19

Jan 11
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19

Royalty Pharma: A Pharma-Like Company Without The Same Risks

Dec 27

Royalty Pharma Provides Unique Diversity To A Biopharma Portfolio

Oct 27

Royalty Pharma (RPRX) MorphoSys Transaction Call

Jun 11

Royalty Pharma: A Potentially Long-Term Dividend Investment

May 04

Key Things To Watch Out For If You Are After Royalty Pharma plc's (NASDAQ:RPRX) 1.6% Dividend

Mar 08
Key Things To Watch Out For If You Are After Royalty Pharma plc's (NASDAQ:RPRX) 1.6% Dividend

Do Insiders Own Lots Of Shares In Royalty Pharma plc (NASDAQ:RPRX)?

Feb 01
Do Insiders Own Lots Of Shares In Royalty Pharma plc (NASDAQ:RPRX)?

Royalty Pharma raises dividend by 13% to $0.17 per share

Jan 08

Shareholder Returns

RPRXUS PharmaceuticalsUS Market
7D-4.9%-2.0%-2.7%
1Y-33.3%11.9%16.8%

Return vs Industry: RPRX underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.

Return vs Market: RPRX underperformed the US Market which returned 15.1% over the past year.

Price Volatility

Is RPRX's price volatile compared to industry and market?
RPRX volatility
RPRX Average Weekly Movement2.8%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement5.5%
10% most volatile stocks in US Market14.2%
10% least volatile stocks in US Market2.5%

Stable Share Price: RPRX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: RPRX's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996n/aPablo Legorretahttps://www.royaltypharma.com

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Royalty Pharma plc Fundamentals Summary

How do Royalty Pharma's earnings and revenue compare to its market cap?
RPRX fundamental statistics
Market CapUS$15.97b
Earnings (TTM)US$254.95m
Revenue (TTM)US$2.36b

46.9x

P/E Ratio

5.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RPRX income statement (TTM)
RevenueUS$2.36b
Cost of RevenueUS$973.94m
Gross ProfitUS$1.39b
Other ExpensesUS$1.13b
EarningsUS$254.95m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.57
Gross Margin58.76%
Net Profit Margin10.80%
Debt/Equity Ratio72.6%

How did RPRX perform over the long term?

See historical performance and comparison

Dividends

3.0%

Current Dividend Yield

136%

Payout Ratio